Features | Partner Sites | Information | LinkXpress
Sign In
JIB
BioConferenceLive
GLOBETECH PUBLISHING

Human Cell Line Produces High-Quality RSV for Vaccine Production

By BiotechDaily International staff writers
Posted on 23 Mar 2014
Image: Electron micrograph reveals the morphologic traits of the respiratory syncytial virus (RSV). The virion is variable in shape, and size (average diameter of between 120–300 nm). RSV is the most common cause of bronchiolitis and pneumonia among infants and children under one year of age (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
Image: Electron micrograph reveals the morphologic traits of the respiratory syncytial virus (RSV). The virion is variable in shape, and size (average diameter of between 120–300 nm). RSV is the most common cause of bronchiolitis and pneumonia among infants and children under one year of age (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
Cooperation between German and American biotechnology companies may pave the way for development of a vaccine to prevent RSV (respiratory syncytial virus) respiratory infections, which have been estimated to cause nearly 7% of the deaths of infants that die during their first year of life.

The companies involved are CEVEC Pharmaceuticals (Cologne, Germany), a clinical stage pharmaceutical company focusing on the development of highly potent protein and vaccine expression systems based on human CAP cells and Paragon Bioservices Inc. (Baltimore, MD, USA), a leading American biopharmaceutical contract manufacturer.

CEVEC has developed a new and proprietary expression system for biopharmaceuticals offering significant advantages over existing production technologies. Their CAP cells are an immortalized cell line derived from primary human amniocytes that meet the highest ethical and regulatory standards. CEVEC´s CAP cells have proven highly efficient in the production of a broad range of otherwise difficult to express glycoproteins. These molecules are produced at high titers with authentic post-translational modifications in serum-free suspension culture. Their ability to generate human glycosylation patterns also makes CAP cells a valuable tool for vaccine production.

The CEVEC/Paragon project has succeeded in producing RSV in CAP cells that show a high-level of functional G-protein resulting in a very effective RSV vaccine with positive impact on attenuated-vaccine studies.

"Again CAP cells prove their enormous potential and significant advantages over many currently used production systems for vaccines," said Dr. Rainer Lichtenberger, COO of CEVEC. "Next to Cytomegalovirus, influenza, and others, this is another striking example that CAP cells can efficiently propagate disease relevant human viruses. We were very pleased to work with Paragon on this project and benefited from their experience in vaccine production. This collaboration was extremely pleasant and successful."

Marco Chacón, CEO of Paragon said, "This teamwork pays not only for CEVEC, but also for Paragon. With use of CAP cells we can offer our customers a unique production system to meet the challenges of their vaccine target. With this highly ambitious project we have again proven our expertise in this competitive business."

Related Links:

CEVEC Pharmaceuticals
Paragon Bioservices Inc.



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Microcomputed tomography images (top) and histology images (bottom) of the knees of mice fed a very high fat diet containing omega-3 fatty acid supplement (left) or only omega-6 fatty acids (right) after a knee injury. The omega-6 diet showed abnormal bone remodeling and calcified tissue formation in the joint (white arrow). The omega-6 diet also showed significant loss of cartilage (red staining, yellow arrowhead) and increased joint inflammation (Photo courtesy of Duke University).

Dietary Omega-3 Fatty Acids Moderate Severity of Osteoarthritis in a Mouse Model

Researchers working with an osteoarthritis (OA) obese mouse model found that the fat content of the animals' diet contributed more to the development or arrest of OA than did body weight.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.